Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) EBIT (2016 - 2025)

Historic EBIT for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to -$2.7 million.

  • Evogene's EBIT rose 5398.65% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.5 million, marking a year-over-year increase of 3492.34%. This contributed to the annual value of -$18.8 million for FY2024, which is 2906.29% up from last year.
  • Evogene's EBIT amounted to -$2.7 million in Q3 2025, which was up 5398.65% from -$3.1 million recorded in Q2 2025.
  • In the past 5 years, Evogene's EBIT registered a high of -$2.7 million during Q3 2025, and its lowest value of -$8.7 million during Q4 2021.
  • Moreover, its 5-year median value for EBIT was -$6.3 million (2021), whereas its average is -$6.0 million.
  • In the last 5 years, Evogene's EBIT skyrocketed by 5648.87% in 2022 and then crashed by 10169.22% in 2023.
  • Over the past 5 years, Evogene's EBIT (Quarter) stood at -$8.7 million in 2021, then soared by 56.49% to -$3.8 million in 2022, then plummeted by 101.69% to -$7.6 million in 2023, then skyrocketed by 40.13% to -$4.6 million in 2024, then surged by 40.35% to -$2.7 million in 2025.
  • Its last three reported values are -$2.7 million in Q3 2025, -$3.1 million for Q2 2025, and -$4.1 million during Q1 2025.